针酸对子宫内膜癌细胞生长和迁移的抑制作用及其与多克索鲁比的协同抑制
Yi-Ting Kuo1, Chi-Chang Chang2,3,4, Yu Chang2,3
1Graduate Institute of Medicine, College of Medicine, I-Shou University, Kaohsiung 824005, Taiwan.
Pharmaceuticals (Basel, Switzerland)
|November 27, 2025
概括
酸 (SA) 抑制子宫内膜癌细胞的生长和迁移,增强化疗效. 它还通过减少炎症和氧化应激来保护正常的子宫内膜细胞.
科学领域:
- 妇科 妇科医生 妇科
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 子宫内膜癌 (EC) 是一种流行的妇科恶性瘤.
- 酸 (SA) 是一种类化合物,具有抗氧化,抗炎和抗血管性质.
- 研究SA对EC的影响及其作为辅助疗法的潜力至关重要.
研究的目的:
- 评估SA对子宫内膜癌 (EC) 细胞增殖和迁移的影响.
- 评估SA对正常子宫内膜层细胞 (HESC) 的保护作用.
- 探索SA与化疗剂的协同抗癌潜力.
主要方法:
- 细胞活力测试 (MTT,核光,克隆基因存活率).
- 细胞迁移测定 (伤口关闭,Transwell).
- 基因表达分析 (RT-PCR) 和途径分析 (NF-κB, Nrf2).
主要成果:
- SA显著抑制了EC细胞的增殖 (IC50=27.22μM) 和迁移.
- 在EC细胞中,SA诱导了细胞亡和细胞循环停止.
- 在正常的HESC中,SA显示出细胞保护作用,减少炎症和氧化应激.
结论:
- SA对子宫内膜癌细胞表现出强大的抗癌活性.
- 氨酸增强了多克索鲁比化疗的疗效.
- 作为EC的选择性辅助疗法,SA显示出有前途的前景,保护正常细胞.
更多相关视频
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
11.4K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.7K
相关概念视频
Combined Effects of Drugs: Synergism
6.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
6.7K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
